ZYCLARA

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Estonia, France, Ireland, Italy, Lithuania, Netherlands, Poland, Spain, UK.

Active ingredients

The drug ZYCLARA contains one active pharmaceutical ingredient (API):

1	Imiquimod UNII P1QW714R7M - IMIQUIMOD
	Imiquimod is an immune response modifier. Saturable binding studies suggest a membrane receptor for imiquimod exists on responding immune cells. Imiquimod has no direct antiviral activity.
	Read more about Imiquimod

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZYCLARA Cream	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D06BB10	Imiquimod	D Dermatologicals → D06 Antibiotics and chemotherapeutics for dermatological use → D06B Chemotherapeutics for topical use → D06BB Antivirals
Discover more medicines within D06BB10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02340445
EE	Ravimiamet	1592995, 1593008, 1593019
ES	Centro de información online de medicamentos de la AEMPS	12783002
FR	Base de données publique des médicaments	69349666
GB	Medicines & Healthcare Products Regulatory Agency	217359, 369189
IT	Agenzia del Farmaco	043585013, 043585025, 043585037
LT	Valstybinė vaistų kontrolės tarnyba	1067334, 1067335, 1067336
NL	Z-Index G-Standaard, PRK	132020
PL	Rejestru Produktów Leczniczych	100288038
US	FDA, National Drug Code	99207-270, 99207-271, 99207-276